| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4789.7 | 6064.7 | 4304.5 |
| Other income | 86.2 | 173.5 | 47.0 |
| Total income | 4875.9 | 6238.2 | 4351.5 |
| Profit before exceptional items & tax | 257.2 | 506.0 | 213.1 |
| Profit before tax | 257.2 | 506.0 | 213.1 |
| Net profit | 184.6 | 444.7 | 160.1 |
| Operating margin | 5.3% | 8.1% | 4.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +15.30% |
|---|---|
| Net profit, quarter on quarter | -58.50% |
| Revenue, year on year | +11.30% |
| Operating profit, year on year | +3.00% |
| Operating profit, quarter on quarter | -48.60% |
NSE results filing, NSE: MEDICAMEQ. Figures extracted from the filing.
Medicamen Biotech Ltd: key numbers
- Share price
- ₹313.25
- Market cap
- ₹424.9 Cr
- Revenue (annual)
- ₹197.8 Cr
- Net profit (annual)
- ₹9.64 Cr
- P/E (TTM)
- 39.2×Sector 47.3×
- Promoter holding
- 40.46%+0.00% QoQ
- FII holding
- 0.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medicamen Biotech Ltd
All →Medicamen Biotech Annual General Meeting
Medicamen Biotech Limited held its 33rd Annual General Meeting on September 26, 2026. The meeting concluded after discussing standard business and special resolutions.
Medicamen Biotech Annual General Meeting
Medicamen Biotech Limited filed its notice for the 33rd Annual General Meeting scheduled for September 26, 2026, alongside the Integrated Annual Report for FY 2025-26.
Medicamen Biotech Annual General Meeting
Medicamen Biotech Limited has fixed September 19, 2026, as the record date for its final dividend. The book closure is scheduled from September 20 to September 26, 2026.
Medicamen Biotech Q1 FY27 Results: Net Profit ₹1.8 Cr, Up 12.5% YoY
Medicamen Biotech Ltd reported revenue from operations of ₹47.9 Cr (+11.4% YoY) and net profit of ₹1.8 Cr (+12.5% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.8 Cr · +12.5% YoY
Medicamen Biotech Board Meeting Date
Medicamen Biotech Limited has scheduled a board meeting for August 14, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Medicamen Biotech Fund Raise of ₹53.57 Cr
Medicamen Biotech Limited reported zero deviation in the utilization of ₹53.57 Crore raised via preferential issue. The funds are being deployed for drug development and expansion.
- Value
- ₹53.57 Cr